Appointment of Dr Adrian Kilcoyne to SAB

AI SummaryClose X

Poolbeg Pharma plc has announced the appointment of Dr. Adrian Kilcoyne to its Scientific Advisory Board, bringing over 20 years of clinical expertise in oncology and immunology drug development, with a particular focus on haematological malignancies, T-cell therapies, and Cytokine Release Syndrome. Dr. Kilcoyne's extensive background includes leadership roles at Cellectis SA, Celularity Inc., and Humanigen Inc., as well as experience at major pharmaceutical companies like AstraZeneca and Roche. His appointment is expected to be invaluable as Poolbeg progresses its lead asset, POLB 001, through the TOPICAL trial, aiming to transform cancer immunotherapy by preventing the life-threatening side effect of Cytokine Release Syndrome.

Disclaimer*

UK 100

Latest directors dealings